Crinetics Pharmaceuticals (CRNX) Shares Outstanding (2017 - 2026)

Crinetics Pharmaceuticals has reported Shares Outstanding for 10 years, with the latest figure at $105.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 12.61% year-over-year to $105.3 million; the trailing twelve-month figure through Mar 2026 stood at $105.3 million (up 12.61% YoY), and the FY2025 full-year result was $95.6 million, up 2.85% from the prior year.
• Shares Outstanding for Q1 2026 stood at $105.3 million, up from $95.6 million in the prior quarter.
• The five-year high for Shares Outstanding was $105.3 million in Q1 2026, with the low at $4.8 million in Q1 2022.
• Average Shares Outstanding over 5 years is $72.0 million, with a median of $78.5 million recorded in 2024.
• Year-over-year, Shares Outstanding plunged 85.52% in 2022 and jumped 1029.5% in 2023.
• Tracing CRNX's Shares Outstanding over 5 years: stood at $53.9 million in 2022, then climbed by 26.54% to $68.2 million in 2023, then jumped by 36.31% to $92.9 million in 2024, then gained by 2.85% to $95.6 million in 2025, then advanced by 10.19% to $105.3 million in 2026.
• The last three Shares Outstanding figures came in at $105.3 million (Q1 2026), $95.6 million (Q4 2025), and $94.5 million (Q3 2025), per Business Quant data.

Peer Comparison